143 related articles for article (PubMed ID: 22915655)
21. Medicine. Why a new cancer drug works well, in some patients.
Marx J
Science; 2004 Apr; 304(5671):658-9. PubMed ID: 15118127
[No Abstract] [Full Text] [Related]
22. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
23. Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.
Gauthier H; Douchet G; Lehmann-Che J; Meignin V; Raynaud C; Sabatier P; de Cremoux H; Poirot B; Culine S; Pouessel D; de Cremoux P
J Thorac Oncol; 2014 Oct; 9(10):e78-9. PubMed ID: 25521408
[No Abstract] [Full Text] [Related]
24. Predictive tests for EGFR inhibitors.
Lynch TJ
Clin Adv Hematol Oncol; 2005 Sep; 3(9):678-9. PubMed ID: 16224439
[No Abstract] [Full Text] [Related]
25. Targeting resistance in lung cancer.
Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718
[No Abstract] [Full Text] [Related]
26. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
Zalcman G
Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
[No Abstract] [Full Text] [Related]
27. EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.
Clark J; Cools J; Gilliland DG
PLoS Med; 2005 Mar; 2(3):e75. PubMed ID: 15736989
[TBL] [Abstract][Full Text] [Related]
28. The cellular origins of drug resistance in cancer.
Oxnard GR
Nat Med; 2016 Mar; 22(3):232-4. PubMed ID: 26937615
[No Abstract] [Full Text] [Related]
29. EGFR testing in lung cancer is ready for prime time.
Hirsch FR; Bunn PA
Lancet Oncol; 2009 May; 10(5):432-3. PubMed ID: 19410185
[No Abstract] [Full Text] [Related]
30. K-ras mutations in lung cancer: the "mysterious mutation".
Hirsch FR
Clin Lung Cancer; 2006 Jul; 8(1):11-2. PubMed ID: 16870039
[No Abstract] [Full Text] [Related]
31. Targeting targeted therapy.
Green MR
N Engl J Med; 2004 May; 350(21):2191-3. PubMed ID: 15118072
[No Abstract] [Full Text] [Related]
32. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].
Chen XX; Zhou CC
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756
[No Abstract] [Full Text] [Related]
33. [Acquired resistance mechanisms to EGFR-TKIs in EGFR mutated lung cancers].
Suda K; Mitsudomi T
Nihon Rinsho; 2012 Nov; 70 Suppl 8():341-5. PubMed ID: 23513863
[No Abstract] [Full Text] [Related]
34. Cancer. A bull's eye for targeted lung cancer therapy.
Minna JD; Gazdar AF; Sprang SR; Herz J
Science; 2004 Jun; 304(5676):1458-61. PubMed ID: 15178790
[No Abstract] [Full Text] [Related]
35. Chasing mutations in the epidermal growth factor in lung cancer.
Dowell JE; Minna JD
N Engl J Med; 2005 Feb; 352(8):830-2. PubMed ID: 15728818
[No Abstract] [Full Text] [Related]
36. Unlocking the biological clues of lung cancer.
Hanna N
J Thorac Oncol; 2008 Aug; 3(8):809-10. PubMed ID: 18670296
[No Abstract] [Full Text] [Related]
37. An Eigen-Binding Site Based Method for the Analysis of Anti-EGFR Drug Resistance in Lung Cancer Treatment.
Ma L; Wang DD; Zou B; Yan H
IEEE/ACM Trans Comput Biol Bioinform; 2017; 14(5):1187-1194. PubMed ID: 27187970
[TBL] [Abstract][Full Text] [Related]
38. Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases.
Pallan L; Taniere P; Koh P
J Thorac Oncol; 2014 Oct; 9(10):e75. PubMed ID: 25521406
[No Abstract] [Full Text] [Related]
39. The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.
Toyooka S; Date H; Uchida A; Kiura K; Takata M
Clin Cancer Res; 2007 Jun; 13(11):3431; author reply 3431-2. PubMed ID: 17545553
[No Abstract] [Full Text] [Related]
40. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors.
Engelman JA; Cantley LC
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4372s-4376s. PubMed ID: 16857813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
